Peritoneal Cancer

• CLINICAL_TRIALS trial_result · 2022-10-05
  Clinical Trial Update: Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation [Phase 2]

  Phase 2 trial evaluating the combination of olaparib, durvalumab, and tremelimumab in patients with BRCA1/BRCA2-mutated recurrent or refract…

• CLINICAL_TRIALS trial_result · 2022-09-27
  Clinical Trial Update: Perfusion CT in Predicting Outcomes in Ovarian, Fallopian, or Peritoneal Cancer With Bevacizumab [NA]

  Clinical trial assessing perfusion CT to predict outcomes in ovarian, fallopian tube, or peritoneal cancer treated with bevacizumab; the stu…

• CLINICAL_TRIALS trial_result · 2022-09-21
  Clinical Trial Update: Vaccine Therapy, Paclitaxel, and Carboplatin in Treating Patients Who Are Undergoing Surgery for Stage III or Stage IV Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer [Phase 2]

  Phase 2 trial evaluating a vaccine therapy with paclitaxel and carboplatin in patients undergoing surgery for advanced ovarian cancer, prima…

• CLINICAL_TRIALS trial_result · 2022-07-26
  Clinical Trial Update: Pembrolizumab and Carboplatin in Treating Patients With Relapsed or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer [Phase 1, Phase 2]

  A Phase 1/2 clinical trial evaluating pembrolizumab in combination with carboplatin for relapsed or refractory ovarian, fallopian tube, or p…

• CLINICAL_TRIALS trial_result · 2022-06-24
  Clinical Trial Update: Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer [Phase 1, Phase 2]

  Clinical trial update for paclitaxel and ganetespib in recurrent ovarian, fallopian tube, or primary peritoneal cancer; study terminated wit…

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• CLINICAL_TRIALS trial_result · 2022-05-31
  Clinical Trial Update: Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1 [Phase 1, Phase 2]

  Phase 1/2 trial evaluating NY-ESO-1–targeted T-cell therapy with or without decitabine in patients with NY-ESO-1–expressing advanced cancers…

• CLINICAL_TRIALS trial_result · 2022-04-25
  Clinical Trial Update: Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Advanced Epithelial Ovarian Carcinomas [Phase 2]

  Phase 2 trial investigating autologous dendritic cells loaded with autologous tumor-associated antigens for advanced epithelial ovarian carc…

• CLINICAL_TRIALS trial_result · 2022-03-15
  Clinical Trial Update: BromAc for Recurrent Peritoneal Mucinous Tumour or Pseudomyxoma Peritonei [Phase 2]

  Phase 2 clinical trial update for BromAc in recurrent pseudomyxoma peritonei and peritoneal mucinous tumors; current status is unknown.

• CLINICAL_TRIALS trial_result · 2022-02-18
  Clinical Trial Update: Four Quadrants Transverse Abdominus Plane (4Q-TAP) Block With Plain and Liposomal Bupivacaine vs. Thoracic Epidermal Analgesia (TEA) in Patients Undergoing Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy (CRS-HIPEC) on an Enhanced Recovery Pathway [Phase 3]

  A Phase 3 trial comparing four quadrants transverse abdominus plane block with plain and liposomal bupivacaine versus thoracic epidermal ana…

• CLINICAL_TRIALS trial_result · 2022-02-11
  Clinical Trial Update: ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients [Phase 3]

  Phase 3 ARIEL4 trial comparing rucaparib to chemotherapy in BRCA-mutant ovarian, fallopian tube, or primary peritoneal cancer has completed …

• CLINICAL_TRIALS trial_result · 2022-01-14
  Clinical Trial Update: IGFBP-2 Vaccine and Combination Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Undergoing Surgery [Phase 2]

  Phase 2 trial update on IGFBP-2 vaccine with combination chemotherapy for stage III-IV ovarian, fallopian tube, or primary peritoneal cancer…

• CLINICAL_TRIALS trial_result · 2021-11-15
  Clinical Trial Update: A Clinical Trial of Autologous Oxidized Tumor Cell Lysate Vaccine For Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer [Phase 1, Phase 2]

  Clinical trial update for an autologous oxidized tumor cell lysate vaccine in recurrent ovarian/fallopian tube/primary peritoneal cancer; tr…

• CLINICAL_TRIALS trial_result · 2021-09-16
  Clinical Trial Update: Vaccine Therapy in Treating Patients With Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer [Phase 1]

  Phase 1 clinical trial update for a vaccine therapy in ovarian epithelial, primary peritoneal, or fallopian tube cancer with completed statu…

• CLINICAL_TRIALS trial_result · 2021-09-02
  Clinical Trial Update: Physical Activity Monitored by Fitbit Charge 2 in Improving Quality of Life in Participants With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer [Phase 2]

  Phase 2 study examining whether physical activity tracked by Fitbit Charge 2 improves quality of life in participants with recurrent ovarian…

• CLINICAL_TRIALS trial_result · 2021-09-01
  Clinical Trial Update: Trial of Surufatinib Combined With Toripalimab in the Treatment of Peritoneal Metastatic Carcinoma of Gastrointestinal or Primary Peritoneal Cancer [Phase 2]

  Phase 2 trial evaluating surufatinib with toripalimab for refractory metastatic digestive system carcinoma and primary peritoneal cancer is …

• CLINICAL_TRIALS trial_result · 2021-08-27
  Clinical Trial Update: Trial on NIraparib-TSR-042 (Dostarlimab) vs Physician's Choice CHEmotherapy in Recurrent, Ovarian, Fallopian Tube or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment [Phase 3]

  A Phase 3 trial comparing Niraparib-TSR-042 (Dostarlimab) to physician's choice chemotherapy in recurrent ovarian/fallopian tube/primary per…

• CLINICAL_TRIALS trial_result · 2021-08-27
  Clinical Trial Update: Carboplatin-Paclitaxel-Bevacizumab vs Carbo-Pacli-Beva-Rucaparib vs Carbo-Pacli-Ruca, Selected According to HRD Status, in Patients With Advanced Ovarian, Primary Peritoneal and Fallopian Tube Cancer, Preceded by a Phase I Dose Escalation Study on Ruca-Beva Combination [Phase 1, Phase 2]

  A phase 1/2 trial comparing carboplatin-paclitaxel-bevacizumab with alternative regimens including rucaparib, selected by HRD status, in adv…

• CLINICAL_TRIALS trial_result · 2021-08-25
  Clinical Trial Update: Trial on Trabectedin (ET-743) vs Clinician's Choice Chemotherapy in Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancers of BRCA Mutated or BRCAness Phenotype Patients [Phase 3]

  Phase 3 trial comparing trabectedin (ET-743) to clinician's choice chemotherapy in recurrent ovarian, primary peritoneal, or fallopian tube …

• CLINICAL_TRIALS trial_result · 2021-08-03
  Clinical Trial Update: Pembrolizumab Combined With PLD For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal Cancer [Phase 2]

  A Phase 2 trial evaluating pembrolizumab in combination with pegylated liposomal doxorubicin for recurrent platinum-resistant ovarian, fallo…

• CLINICAL_TRIALS trial_result · 2021-07-30
  Clinical Trial Update: Efficacy and Safety of SG001 Combined With PLD in Patients With Platinum-resistant Relapsed EOC [Phase 2]

  Phase 2 clinical trial evaluating efficacy and safety of SG001 in combination with PLD for platinum-resistant relapsed epithelial ovarian ca…

• CLINICAL_TRIALS trial_result · 2021-07-13
  Clinical Trial Update: A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2) [Phase 2]

  Phase 2 study ARIEL2 evaluating rucaparib in platinum-sensitive relapsed high-grade ovarian/fallopian tube/primary peritoneal cancer complet…

• CLINICAL_TRIALS trial_result · 2021-06-18
  Clinical Trial Update: Study of DPX-Survivac Therapy in Patients With Recurrent Ovarian Cancer [Phase 1, Phase 2]

  Clinical trial update for DPX-Survivac in recurrent ovarian-related cancers, spanning Phase 1 and Phase 2.

• CLINICAL_TRIALS trial_result · 2021-06-16
  Clinical Trial Update: Intraperitoneal Infusion of Autologous Monocytes With Sylatron (Peginterferon Alfa-2b) and Actimmune (Interferon Gamma-1b) in Women With Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer [Phase 1]

  Phase 1 trial evaluating intraperitoneal infusion of autologous monocytes with Sylatron (peginterferon alfa-2b) and Actimmune (interferon ga…

• CLINICAL_TRIALS trial_result · 2021-06-10
  Clinical Trial Update: Surgery or Chemotherapy in Recurrent Ovarian Cancer (SOC 1 Trial)? [Phase 3]

  Phase 3 trial comparing surgery versus chemotherapy in recurrent ovarian cancer; status currently unknown.

• CLINICAL_TRIALS trial_result · 2021-05-12
  Clinical Trial Update: Guadecitabine and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer [Phase 2]

  Phase 2 trial evaluating guadecitabine plus pembrolizumab in recurrent ovarian, primary peritoneal, or fallopian tube cancer has completed w…